The EU Malaria Fund is a public-private partnership between the European Union, International Organizations, corporations, and organized civic society, providing a novel funding instrument to address market failures in infectious diseases with significant relevance to public health globally. It has been initiated by kENUP Foundation, the Fund's supreme organ is the Scientific Advisory Council. The Fund was inaugurated during a public ceremony held online on June 3, 2020. 

Therefore, the EU Malaria Fund has successfully accomplished its mission earlier than expected. Therefore, on June 30, 2021, its investment period has ended. The Fund looks back at successfully initiating more than two dozen novel scientific approaches to the fight against malaria, and on financing numerous innovative companies. 

The EU Malaria Fund aims to conclude all investments already in concrete negotiations, following positive decision by all its Committees, and disburse those to the companies in case the respective financing contracts will be signed timely, and provided that the preconditions for disbursements are fulfilled prior to September 30, 2021. Thereafter, the EU Malaria Fund will service the investment portfolio until the end of the post-investment phase period. Accordingly, the Fund’s governance will for the most part remain intact. No additional funding and investments will be made by the Fund, and it will thus not call upon further disbursements from its investors. 

The EU Malaria Fund’s Investment Decision Committee (IDC) will be dissolved, while the Scientific Advisory Council (SAC) with its nine distinguished members will serve as eradicateMalaria’s Scientific Advisory Board (SAB) as of July 1, 2021. kENUP Foundation will be introducing the EU Malaria Fund’s portfolio companies to relevant third parties in support of their future financing needs. Investments related to the manufacturing of current, and especially next-generation anti-malarials in Sub-Saharan Africa will be pursued in coordination with Medicines for Malaria Venture (MMV).

During its investment period, The EU Malaria Fund has aimed to

• support the control, and potentially eradication, of malaria;
• provide venture loans at preferential terms to incorporated, scientifically promising projects not yet pursued by the pharmaceutical industry, thus helping to extend the deal-flow in the domain of tropical diseases;
• fund platform projects allowing for secondary exploitations of their anti-malaria assets, for example into COVID-19; 
• work with a thoroughly considered portfolio of pre-selected companies, thus ensuring its ability to fund malaria R&D right away; 
• serve as a “case-in-point” for the set-up of similar funding instruments to address other pressing medical needs with underlying market failures comparable to those in malaria (for example: NDDs, AMR).